Artiva Biotherapeutics, Common Stock Market Value
| ARTV Stock | 11.04 0.64 6.15% |
| Symbol | Artiva |
Artiva Biotherapeutics, Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artiva Biotherapeutics,. If investors know Artiva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artiva Biotherapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.48) | Revenue Per Share 0.485 | Quarterly Revenue Growth (0.75) | Return On Equity (0.44) |
The market value of Artiva Biotherapeutics, is measured differently than its book value, which is the value of Artiva that is recorded on the company's balance sheet. Investors also form their own opinion of Artiva Biotherapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Artiva Biotherapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artiva Biotherapeutics,'s market value can be influenced by many factors that don't directly affect Artiva Biotherapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artiva Biotherapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Artiva Biotherapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artiva Biotherapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Artiva Biotherapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Artiva Biotherapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Artiva Biotherapeutics,.
| 11/19/2024 |
| 12/19/2024 |
If you would invest 0.00 in Artiva Biotherapeutics, on November 19, 2024 and sell it all today you would earn a total of 0.00 from holding Artiva Biotherapeutics, Common or generate 0.0% return on investment in Artiva Biotherapeutics, over 30 days. Artiva Biotherapeutics, is related to or competes with Paltalk, SEI Investments, GAMCO Global, Royalty Management, Ameriprise Financial, SmartStop Self, and Fidus Investment. Artiva Biotherapeutics, is entity of United States More
Artiva Biotherapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Artiva Biotherapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Artiva Biotherapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.33 | |||
| Information Ratio | 0.0552 | |||
| Maximum Drawdown | 32.08 | |||
| Value At Risk | (10.48) | |||
| Potential Upside | 10.28 |
Artiva Biotherapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Artiva Biotherapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Artiva Biotherapeutics,'s standard deviation. In reality, there are many statistical measures that can use Artiva Biotherapeutics, historical prices to predict the future Artiva Biotherapeutics,'s volatility.| Risk Adjusted Performance | 0.0561 | |||
| Jensen Alpha | 0.376 | |||
| Total Risk Alpha | 0.2281 | |||
| Sortino Ratio | 0.0585 | |||
| Treynor Ratio | 0.5453 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Artiva Biotherapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Artiva Biotherapeutics, Backtested Returns
At this stage we consider Artiva Stock to be slightly risky. Artiva Biotherapeutics, secures Sharpe Ratio (or Efficiency) of 0.0028, which signifies that the company had a 0.0028% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Artiva Biotherapeutics, Common, which you can use to evaluate the volatility of the firm. Please confirm Artiva Biotherapeutics,'s Downside Deviation of 6.33, mean deviation of 5.09, and Risk Adjusted Performance of 0.0561 to double-check if the risk estimate we provide is consistent with the expected return of 0.0186%. The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Artiva Biotherapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Artiva Biotherapeutics, is expected to be smaller as well. Artiva Biotherapeutics, right now shows a risk of 6.59%. Please confirm Artiva Biotherapeutics, potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Artiva Biotherapeutics, will be following its price patterns.
Auto-correlation | -0.76 |
Almost perfect reverse predictability
Artiva Biotherapeutics, Common has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Artiva Biotherapeutics, time series from 19th of November 2024 to 4th of December 2024 and 4th of December 2024 to 19th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Artiva Biotherapeutics, price movement. The serial correlation of -0.76 indicates that around 76.0% of current Artiva Biotherapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.76 | |
| Spearman Rank Test | -0.73 | |
| Residual Average | 0.0 | |
| Price Variance | 0.48 |
Artiva Biotherapeutics, lagged returns against current returns
Autocorrelation, which is Artiva Biotherapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Artiva Biotherapeutics,'s stock expected returns. We can calculate the autocorrelation of Artiva Biotherapeutics, returns to help us make a trade decision. For example, suppose you find that Artiva Biotherapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Artiva Biotherapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Artiva Biotherapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Artiva Biotherapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Artiva Biotherapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Artiva Biotherapeutics, Lagged Returns
When evaluating Artiva Biotherapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Artiva Biotherapeutics, stock have on its future price. Artiva Biotherapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Artiva Biotherapeutics, autocorrelation shows the relationship between Artiva Biotherapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Artiva Biotherapeutics, Common.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.